FDA approves Votrient® for treatment of patients with certain types of advanced soft tissue sarcoma
Issued: Thursday 26 April 2012, Philadelphia GlaxoSmithKline plc [LSE/NYSE: GSK] announced today that the U.S. Food and Drug Administration (FDA) has approved Votrient ® (pazopanib) for the treatment of patients with advanced soft tissue sarcoma who …